Logo image of INVA

INNOVIVA INC (INVA) Stock Fundamental Analysis

NASDAQ:INVA - Nasdaq - US45781M1018 - Common Stock - Currency: USD

21.4  +0.03 (+0.14%)

After market: 21.4 0 (0%)

Fundamental Rating

6

Overall INVA gets a fundamental rating of 6 out of 10. We evaluated INVA against 195 industry peers in the Pharmaceuticals industry. INVA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. INVA is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make INVA suitable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

INVA had negative earnings in the past year.
INVA had a positive operating cash flow in the past year.
INVA had positive earnings in each of the past 5 years.
INVA had a positive operating cash flow in each of the past 5 years.
INVA Yearly Net Income VS EBIT VS OCF VS FCFINVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

1.2 Ratios

INVA has a better Return On Assets (-4.76%) than 75.38% of its industry peers.
The Return On Equity of INVA (-9.23%) is better than 77.95% of its industry peers.
The Return On Invested Capital of INVA (13.88%) is better than 91.28% of its industry peers.
INVA had an Average Return On Invested Capital over the past 3 years of 11.38%. This is below the industry average of 14.70%.
The 3 year average ROIC (11.38%) for INVA is below the current ROIC(13.88%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -4.76%
ROE -9.23%
ROIC 13.88%
ROA(3y)11.21%
ROA(5y)16.95%
ROE(3y)22.61%
ROE(5y)34.7%
ROIC(3y)11.38%
ROIC(5y)18.16%
INVA Yearly ROA, ROE, ROICINVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200

1.3 Margins

INVA's Profit Margin has declined in the last couple of years.
The Operating Margin of INVA (49.34%) is better than 98.97% of its industry peers.
In the last couple of years the Operating Margin of INVA has declined.
INVA has a Gross Margin of 90.68%. This is amongst the best in the industry. INVA outperforms 94.87% of its industry peers.
Industry RankSector Rank
OM 49.34%
PM (TTM) N/A
GM 90.68%
OM growth 3Y-21.38%
OM growth 5Y-13.2%
PM growth 3Y-54.19%
PM growth 5Y-35.9%
GM growth 3YN/A
GM growth 5YN/A
INVA Yearly Profit, Operating, Gross MarginsINVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so INVA is still creating some value.
The number of shares outstanding for INVA has been reduced compared to 1 year ago.
The number of shares outstanding for INVA has been reduced compared to 5 years ago.
The debt/assets ratio for INVA has been reduced compared to a year ago.
INVA Yearly Shares OutstandingINVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
INVA Yearly Total Debt VS Total AssetsINVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 2.38 indicates that INVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
INVA's Altman-Z score of 2.38 is fine compared to the rest of the industry. INVA outperforms 70.77% of its industry peers.
The Debt to FCF ratio of INVA is 2.29, which is a good value as it means it would take INVA, 2.29 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of INVA (2.29) is better than 92.82% of its industry peers.
A Debt/Equity ratio of 0.40 indicates that INVA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.40, INVA is in line with its industry, outperforming 40.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF 2.29
Altman-Z 2.38
ROIC/WACC1.53
WACC9.08%
INVA Yearly LT Debt VS Equity VS FCFINVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

INVA has a Current Ratio of 2.48. This indicates that INVA is financially healthy and has no problem in meeting its short term obligations.
INVA's Current ratio of 2.48 is in line compared to the rest of the industry. INVA outperforms 44.62% of its industry peers.
A Quick Ratio of 2.30 indicates that INVA has no problem at all paying its short term obligations.
INVA has a Quick ratio (2.30) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.3
INVA Yearly Current Assets VS Current LiabilitesINVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for INVA have decreased strongly by -145.50% in the last year.
The earnings per share for INVA have been decreasing by -33.21% on average. This is quite bad
INVA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.68%.
Measured over the past years, INVA shows a small growth in Revenue. The Revenue has been growing by 6.57% on average per year.
EPS 1Y (TTM)-145.5%
EPS 3Y-52.04%
EPS 5Y-33.21%
EPS Q2Q%-260.87%
Revenue 1Y (TTM)18.68%
Revenue growth 3Y-2.91%
Revenue growth 5Y6.57%
Sales Q2Q%14.37%

3.2 Future

Based on estimates for the next years, INVA will show a very strong growth in Earnings Per Share. The EPS will grow by 99.32% on average per year.
The Revenue is expected to grow by 14.46% on average over the next years. This is quite good.
EPS Next Y259.68%
EPS Next 2Y279.31%
EPS Next 3Y166.36%
EPS Next 5Y99.32%
Revenue Next Year3.16%
Revenue Next 2Y7.79%
Revenue Next 3Y10.57%
Revenue Next 5Y14.46%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INVA Yearly Revenue VS EstimatesINVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
INVA Yearly EPS VS EstimatesINVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

INVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 7.83 indicates a rather cheap valuation of INVA.
Based on the Price/Forward Earnings ratio, INVA is valued cheaper than 89.74% of the companies in the same industry.
INVA is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.39, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 7.83
INVA Price Earnings VS Forward Price EarningsINVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, INVA is valued cheaper than 95.38% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of INVA indicates a rather cheap valuation: INVA is cheaper than 95.90% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.85
EV/EBITDA 5.48
INVA Per share dataINVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
INVA has a very decent profitability rating, which may justify a higher PE ratio.
INVA's earnings are expected to grow with 166.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y279.31%
EPS Next 3Y166.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNOVIVA INC

NASDAQ:INVA (6/12/2025, 8:00:02 PM)

After market: 21.4 0 (0%)

21.4

+0.03 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-29 2025-07-29
Inst Owners115.83%
Inst Owner Change-3.95%
Ins Owners0.97%
Ins Owner Change1.18%
Market Cap1.34B
Analysts82.5
Price Target56.1 (162.15%)
Short Float %14%
Short Ratio10.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-190.64%
Min EPS beat(2)-350.17%
Max EPS beat(2)-31.11%
EPS beat(4)0
Avg EPS beat(4)-200.83%
Min EPS beat(4)-350.17%
Max EPS beat(4)-31.11%
EPS beat(8)3
Avg EPS beat(8)-31.34%
EPS beat(12)5
Avg EPS beat(12)-64.48%
EPS beat(16)7
Avg EPS beat(16)-34.55%
Revenue beat(2)2
Avg Revenue beat(2)4.4%
Min Revenue beat(2)3.7%
Max Revenue beat(2)5.11%
Revenue beat(4)4
Avg Revenue beat(4)13.51%
Min Revenue beat(4)3.7%
Max Revenue beat(4)31.13%
Revenue beat(8)7
Avg Revenue beat(8)10.16%
Revenue beat(12)9
Avg Revenue beat(12)-0.41%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)189.47%
EPS NQ rev (1m)30.3%
EPS NQ rev (3m)4.88%
EPS NY rev (1m)-54.58%
EPS NY rev (3m)-60.93%
Revenue NQ rev (1m)-2.7%
Revenue NQ rev (3m)0.31%
Revenue NY rev (1m)3.59%
Revenue NY rev (3m)6.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.83
P/S 3.63
P/FCF 6.85
P/OCF 6.71
P/B 2.08
P/tB 3.73
EV/EBITDA 5.48
EPS(TTM)-1.01
EYN/A
EPS(NY)2.73
Fwd EY12.77%
FCF(TTM)3.12
FCFY14.59%
OCF(TTM)3.19
OCFY14.91%
SpS5.89
BVpS10.3
TBVpS5.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.76%
ROE -9.23%
ROCE 17.9%
ROIC 13.88%
ROICexc 24.72%
ROICexgc 49.43%
OM 49.34%
PM (TTM) N/A
GM 90.68%
FCFM 52.99%
ROA(3y)11.21%
ROA(5y)16.95%
ROE(3y)22.61%
ROE(5y)34.7%
ROIC(3y)11.38%
ROIC(5y)18.16%
ROICexc(3y)16.17%
ROICexc(5y)24.46%
ROICexgc(3y)28.95%
ROICexgc(5y)34.96%
ROCE(3y)14.67%
ROCE(5y)23.41%
ROICexcg growth 3Y-8.78%
ROICexcg growth 5Y-15.28%
ROICexc growth 3Y-21.15%
ROICexc growth 5Y-17.48%
OM growth 3Y-21.38%
OM growth 5Y-13.2%
PM growth 3Y-54.19%
PM growth 5Y-35.9%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF 2.29
Debt/EBITDA 1.15
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 17.62
Cash Conversion 90.06%
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.3
Altman-Z 2.38
F-Score6
WACC9.08%
ROIC/WACC1.53
Cap/Depr(3y)4.13%
Cap/Depr(5y)2.48%
Cap/Sales(3y)0.45%
Cap/Sales(5y)0.27%
Profit Quality(3y)320.3%
Profit Quality(5y)247.45%
High Growth Momentum
Growth
EPS 1Y (TTM)-145.5%
EPS 3Y-52.04%
EPS 5Y-33.21%
EPS Q2Q%-260.87%
EPS Next Y259.68%
EPS Next 2Y279.31%
EPS Next 3Y166.36%
EPS Next 5Y99.32%
Revenue 1Y (TTM)18.68%
Revenue growth 3Y-2.91%
Revenue growth 5Y6.57%
Sales Q2Q%14.37%
Revenue Next Year3.16%
Revenue Next 2Y7.79%
Revenue Next 3Y10.57%
Revenue Next 5Y14.46%
EBIT growth 1Y66.31%
EBIT growth 3Y-23.66%
EBIT growth 5Y-7.5%
EBIT Next Year-6.31%
EBIT Next 3Y-8.15%
EBIT Next 5YN/A
FCF growth 1Y51.7%
FCF growth 3Y-20.27%
FCF growth 5Y-6.46%
OCF growth 1Y54.88%
OCF growth 3Y-19.65%
OCF growth 5Y-6.03%